CONMED Co. (NYSE:CNMD) Stock Holdings Decreased by Nuveen Asset Management LLC

Nuveen Asset Management LLC lowered its position in shares of CONMED Co. (NYSE:CNMD - Free Report) by 42.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 81,519 shares of the company's stock after selling 59,427 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.26% of CONMED worth $5,579,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in CONMED by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,554 shares of the company's stock worth $1,201,000 after acquiring an additional 664 shares during the last quarter. Gotham Asset Management LLC acquired a new stake in CONMED during the fourth quarter worth approximately $313,000. Graham Capital Management L.P. boosted its position in CONMED by 7.7% during the fourth quarter. Graham Capital Management L.P. now owns 7,214 shares of the company's stock worth $494,000 after acquiring an additional 518 shares during the last quarter. Deutsche Bank AG boosted its position in CONMED by 47.6% during the fourth quarter. Deutsche Bank AG now owns 29,261 shares of the company's stock worth $2,003,000 after acquiring an additional 9,442 shares during the last quarter. Finally, Dean Capital Management boosted its position in CONMED by 64.4% during the fourth quarter. Dean Capital Management now owns 25,575 shares of the company's stock worth $1,750,000 after acquiring an additional 10,019 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on CNMD shares. Stifel Nicolaus lowered shares of CONMED from a "buy" rating to a "hold" rating and decreased their price target for the company from $75.00 to $55.00 in a report on Monday, April 28th. Wells Fargo & Company decreased their price target on shares of CONMED from $70.00 to $57.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. JPMorgan Chase & Co. decreased their price target on shares of CONMED from $70.00 to $58.00 and set a "neutral" rating on the stock in a report on Thursday, May 1st. Wall Street Zen lowered shares of CONMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC decreased their price target on shares of CONMED from $91.00 to $61.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, CONMED has an average rating of "Hold" and a consensus price target of $62.20.

Insiders Place Their Bets

In other news, Director Charles Farkas sold 4,000 shares of the business's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $56.94, for a total value of $227,760.00. Following the completion of the sale, the director now owns 16,346 shares of the company's stock, valued at approximately $930,741.24. The trade was a 19.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.10% of the stock is currently owned by company insiders.

CONMED Stock Down 0.7%

Shares of NYSE:CNMD traded down $0.38 during midday trading on Wednesday, hitting $56.53. 213,324 shares of the company's stock traded hands, compared to its average volume of 443,953. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.06 and a current ratio of 2.30. The company has a market cap of $1.75 billion, a PE ratio of 13.33, a P/E/G ratio of 1.83 and a beta of 1.19. The firm's fifty day moving average price is $55.09 and its two-hundred day moving average price is $63.03. CONMED Co. has a twelve month low of $46.00 and a twelve month high of $78.58.

CONMED (NYSE:CNMD - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.95 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.14. CONMED had a net margin of 10.13% and a return on equity of 14.31%. The firm had revenue of $321.26 million for the quarter, compared to analyst estimates of $313.38 million. During the same quarter in the previous year, the business posted $0.79 EPS. The firm's revenue was up 2.9% compared to the same quarter last year. On average, equities research analysts anticipate that CONMED Co. will post 4.35 EPS for the current fiscal year.

CONMED Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 3rd. Shareholders of record on Friday, June 13th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $0.80 dividend on an annualized basis and a yield of 1.42%. CONMED's dividend payout ratio is currently 21.05%.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.